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Abstract. 
 
We previously demonstrated contrasting 
 
roles for integrin 
 
a
 
 subunits and their cytoplasmic do-
mains in controlling cell cycle withdrawal and the onset 
of terminal differentiation (Sastry, S., M. Lakonishok, 
 
D. Thomas, J. Muschler, and A.F. Horwitz. 1996.
 
 J. Cell 
Biol.
 
 133:169–184). Ectopic expression of the integrin 
 
a
 
5 or 
 
a
 
6A subunit in primary quail myoblasts either de-
creases or enhances the probability of cell cycle with-
drawal, respectively. In this study, we addressed the 
mechanisms by which changes in integrin 
 
a
 
 subunit ra-
tios regulate this decision. Ectopic expression of trun-
cated 
 
a
 
5 or 
 
a
 
6A indicate that the 
 
a
 
5 cytoplasmic
domain is permissive for the proliferative pathway 
whereas the COOH-terminal 11 amino acids of 
 
a
 
6A cy-
toplasmic domain inhibit proliferation and promote dif-
ferentiation. The 
 
a
 
5 and 
 
a
 
6A cytoplasmic domains do 
not appear to initiate these signals directly, but instead 
regulate 
 
b
 
1 signaling. Ectopically expressed IL2R-
 
a
 
5 or 
IL2R-
 
a
 
6A have no detectable effect on the myoblast 
phenotype. However, ectopic expression of the 
 
b
 
1A in-
tegrin subunit or IL2R-
 
b
 
1A, autonomously inhibits dif-
ferentiation and maintains a proliferative state. Per-
turbing 
 
a
 
5 or 
 
a
 
6A ratios also signiﬁcantly affects 
activation of 
 
b
 
1 integrin signaling pathways. Ectopic 
 
a
 
5 
expression enhances expression and activation of paxil-
lin as well as mitogen-activated protein (MAP) kinase 
with little effect on focal adhesion kinase (FAK). In 
contrast, ectopic 
 
a
 
6A expression suppresses FAK and 
MAP kinase activation with a lesser effect on paxillin. 
Ectopic expression of wild-type and mutant forms of 
FAK, paxillin, and MAP/erk kinase (MEK) conﬁrm 
these correlations. These data demonstrate that (a) pro-
liferative signaling (i.e., inhibition of cell cycle with-
drawal and the onset of terminal differentiation) occurs 
through the 
 
b
 
1A subunit and is modulated by the
 
a
 
 subunit cytoplasmic domains; (b) perturbing 
 
a
 
 sub-
unit ratios alters paxillin expression and phosphoryla-
tion and FAK and MAP kinase activation; (c) quantita-
tive changes in the level of adhesive signaling through 
integrins and focal adhesion components regulate the 
decision of myoblasts to withdraw from the cell cycle, in 
part via MAP kinase.
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 proliferation and differentiation are governed
by multiple stimuli including soluble growth fac-
tors, the extracellular matrix (Juliano and Haskill,
1993; Adams and Watt, 1993; Roskelly et al., 1995), and di-
rect cell to cell interactions (Gumbiner, 1996). Whereas
each of these signals uniquely regulates mitogenic re-
sponses and gene activity, the decision of a cell to prolifer-
ate, differentiate, or undergo apoptosis, for example, is an
integrated response to its adhesive and growth factor envi-
ronment (Schwartz and Ingber, 1994; Sastry and Horwitz,
1996). While the mechanisms by which growth factors pro-
duce mitogenic responses and regulate gene expression
are becoming clearer, the pathways through which adhe-
sive interactions modulate these responses are only begin-
ning to emerge (reviewed in Howe et al., 1998).
Several studies demonstrate that integrins control pro-
liferation and differentiation in numerous cell types (Var-
ner et al., 1995; Watt et al., 1993). Clustering of integrins
on the cell surface with ligand-coated microbeads induces
focal adhesion-like structures that recruit numerous mito-
genic signaling proteins to integrin receptors which in-
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clude growth factor receptors (Plopper et al., 1995; Mi-
yamoto et al., 1996), mitogen-activated protein (MAP)
 
1
 
kinase, lipid second messengers, protein phosphatases,
and small GTP-binding proteins (Miyamoto et al., 1995).
Thus integrin-associated focal adhesions serve as signaling
centers where adhesive and mitogenic pathways can inte-
grate. Numerous physical interactions between integrins
or focal adhesion components and mitogenic signaling
proteins have been demonstrated. For example, integrins
can interact with growth factor receptors through adaptor
proteins like IRS-1 (Vuori and Ruoslahti, 1994) and shc
(Mainiero et al., 1995; Wary et al., 1996). Focal adhesion
kinase (FAK) can interact with PI 3-kinase (Chen and
Guan, 1994) and with GRB2 (Schlaepfer et al., 1994).
Through its interaction with GRB2, FAK potentially links
integrin signaling to the ras/MAP kinase pathway.
Whereas these studies show a biochemical coupling be-
tween integrin and growth factor signaling pathways, the
functional significance of these interactions in the context
of the regulation of proliferation and differentiation is not
well understood. MAP kinase stands out as a key point of
convergence between integrin and growth factor pathways
(Chen et al., 1994; Zhu and Assoian, 1995; Miyamoto et al.,
1996; Renshaw et al., 1997) and is required for prolifera-
tion of most cells. However, mitogenic responses can be
controlled by pathways that do not use MAP kinase (Ol-
son et al., 1995; Klippel et al., 1998). In addition, MAP
kinase can modulate other integrin-dependent cell re-
sponses including motility (Klemke et al., 1997) and
integrin activation (Hughes et al., 1997) suggesting that its
activation produces pleiotropic effects. Further, the focal
adhesion proteins FAK and paxillin, which are phosphory-
lated in response to many soluble mitogenic stimuli (re-
viewed in Sastry and Horwitz, 1996) as well as in response
to integrin engagement are likely to play an important role
in integrin-growth factor synergy. Although recent studies
indicate FAK plays a role in cell survival (Frisch et al.,
1996; Hungerford et al., 1996; Ilic et al., 1998) and motility
(Ilic et al., 1995; Cary et al., 1996; Gilmore and Romer,
1996), the role of FAK and paxillin, and variations in the
level of their activation, in mitogenic signaling is not well
understood.
We previously reported contrasting roles for integrin 
 
a
 
subunits in proliferative signaling using myogenic differen-
tiation as a model system (Sastry et al., 1996). Using ec-
topic expression of integrins in primary quail myoblasts we
provided clear biological evidence that integrin 
 
a
 
 subunits
uniquely alter the response of myoblasts to growth factors.
We attributed this effect in part to perturbation of integrin
 
a
 
 subunit ratios (on the order of a three- to fivefold in-
crease in relative expression) which strikingly shifted the
probability that a myoblast would either proliferate or
withdraw from the cell cycle and initiate terminal differen-
tiation. Ectopic expression of the 
 
a
 
5 integrin enhanced the
mitogenic response to favor a much increased probability
of proliferation. In contrast, ectopic expression of the 
 
a
 
6A
integrin decreased the probability of continued prolifera-
tion and promoted differentiation. In addition, we also im-
plicated the 
 
a
 
 subunit cytoplasmic domains in controlling
proliferative versus differentiative signals through inte-
grins.
In this study, we used ectopic expression of these two 
 
a
 
subunits in primary skeletal muscle myoblasts as a conve-
nient tool to drive either the proliferative or differentia-
tive pathway through integrins. We used this approach to
(a) assess the relative contribution of the individual 
 
a
 
 sub-
unit cytoplasmic domains and (b) identify intracellular tar-
gets of integrins that modulate the probability of a myo-
blast to proliferate or withdraw from the cell cycle and
initiate terminal differentiation. First, we demonstrate that
the 
 
a
 
 subunit cytoplasmic domains indirectly regulate pro-
liferative versus differentiative signals through the 
 
b
 
1A
cytoplasmic domain. The 
 
a
 
5 cytoplasmic domain is per-
missive for proliferative signaling while a discrete region
of the 
 
a
 
6A cytoplasmic domain promotes cell cycle with-
drawal. Furthermore, the 
 
b
 
1A cytoplasmic domain is
sufficient to initiate proliferative signals and inhibit dif-
ferentiation. Second, we show that the ectopic 
 
a
 
 sub-
units differentially alter the expression and/or activation
of FAK, paxillin, and MAP kinase. Ectopic expression of
paxillin or CD2-FAK and their mutants recapitulate the
effects of ectopic integrins on myoblast proliferation and
differentiation. The effect of ectopic 
 
a
 
5 or 
 
a
 
6A on prolif-
eration and differentiation can be reversed by altering the
relative activity of MAP/erk kinase (MEK), an upstream
activator of MAP kinase. These results suggest a model in
which proliferative signaling occurs through the integrin
 
b
 
1A subunit which is modulated by the 
 
a
 
 subunit cytoplas-
mic domains. The level of signaling emanating from the
 
b
 
1A subunits controls the level of FAK, paxillin, or MAP
kinase activation. Thus, in addition to changes in integrin
ratios, quantitative changes in the level of focal adhesion
signaling or MAP kinase activation shift the probability
that a myoblast will proliferate or differentiate.
 
Materials and Methods
 
Primary Cell Culture
 
Primary myoblasts were isolated from pectoralis muscle of nine day Japa-
nese quail embryos as previously described (Konigsberg, 1979). In brief,
the breast muscle was dissected from the embryo and myoblasts were dis-
sociated from muscle tissue with 0.1% dispase (Sigma Chemical Co.) in
PBS. The cell suspension was filtered through a Sweeney filter; cells
were seeded onto gelatin-coated tissue culture plates (0.1% gelatin in
PBS). Myoblast cultures were maintained in complete myoblast medium
(DMEM [Sigma Chemical Co.] containing 15% horse serum, 5% chick
embryo extract, 1% pen/strep, and 1.25 mg/ml fungizone [GIBCO BRL]).
Myoblasts were subcultured in trypsin-EDTA (0.06% trypsin, 0.02%
EDTA) and used between passages 1 and 10.
 
Antibodies and Extracellular Matrix Ligands
 
The muscle 
 
a
 
-actinin–specific mAb, 9A2B8, was kindly provided by D.
Fishman (Cornell University, New York, NY) as a hybridoma superna-
tant. mAb VIF4, which recognizes the human 
 
a
 
5 integrin extracellular do-
main was a gift of R. Isberg (Tufts University, Boston, MA). The chicken
 
a
 
6-specific polyclonal antibody, 
 
a
 
6ex (de Curtis et al., 1991), was provided
by L. Reichardt (University of California, San Francisco, CA). mAb 2B7
directed against the extracellular domain of the human 
 
a
 
6 integrin (Shaw
et al., 1993), was a gift of A. Mercurio (Harvard Medical School, Boston,
MA). The mAb 165 is directed against paxillin (Turner et al., 1990). mAb
2A7 directed against FAK (Kanner et al., 1990) and the polyclonal Ab
 
1. 
 
Abbreviations used in this paper:
 
 BCA, bicinchoninic acid; CA-MEK,
constitutively active MEK; FAK, focal adhesion kinase; HA, hemaggluti-
nin; MAP, mitogen-activated protein; MEK, MAP/erk kinase; UT, un-
transfected. 
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BC3 directed against FAK (Shaller et al., 1992) were gifts of T. Parsons
(University of Virginia, Charlottesville, VA). The anti-FAK polyclonal
antibody C-20, was purchased from Santa Cruz Biotechnology, Inc. (Santa
Cruz, CA). The anti-active MAPK polyclonal antibody, which specifically
recognizes dually phosphorylated, activated MAPK, was purchased from
Promega. The anti-MAPK mAb that recognizes erk-1, as well as the anti-
phosphotyrosine antibodies, RC20H and PY20, were purchased from
Transduction Laboratories. The anti-hemagglutinin (HA) mAb, 12CA5,
was purchased from Boehringer Mannheim. The anti-human CD2 mAb,
TS2/18.1.1 was purchased from the Developmental Studies Hybridoma
Bank. TS2/16, a mAb against human 
 
b
 
1 integrin (Hemler et al., 1984) was
from M. Hemler (Dana-Farber Cancer Institute, Boston, MA). Antibody
against the human IL2 receptor was purchased from Boehringer Mann-
heim. Poly-
 
L
 
-lysine was purchased from Sigma Chemical Co. Fibronectin
was purified from human plasma by affinity chromatography as previously
described (Ruoslahti et al., 1982). Laminin was isolated from murine En-
glebreth-Holm-Swarm sarcoma as previously described (Kleinman et al.,
1982).
 
Expression Vectors
 
The human 
 
a
 
5 cDNA in pRSVneo and the chicken 
 
a
 
6 cDNA in pRSVneo
were described previously (Sastry et al., 1996). The chicken 
 
a
 
61044t trun-
cation was constructed by first subcloning a 1.6-kb HindIII-SalI fragment
of the chicken 
 
a
 
6A DNA into M13 and then introducing an in-frame BclI
site at amino acid position 1044 (de Curtis et al, 1991). Mutants were con-
firmed by restriction digestion of M13 clones with BclI and by single
stranded DNA sequencing using the dideoxy-chain termination method
according to the Sequenase™ protocol (United States Biochemical
Corp.). An 800-bp BstXI-SalI fragment containing the mutation was sub-
cloned into pRSVneo
 
a
 
6 partially digested with SalI and completely with
BstXI. The human 
 
a
 
6A and 
 
a
 
6B cDNAs, in the expression plasmid pRc/
CMV (Shaw et al., 1993), were a generous gift of A. Mercurio (Harvard
Medical School, Boston, MA). The pRSVneo-CH8
 
b
 
1 plasmid was con-
structed by subcloning a 1-kb HindIII fragment, containing the CH8
epitope tag, from the CH8
 
b
 
1 pBJ-1 construct received from Y. Takada
(Scripps Research Institute, La Jolla, CA) (Takada and Puzon, 1993) into
pRSVneo
 
b
 
1 expression vector (Reszka et al., 1992). pRSVIL2R-
 
a
 
5 and
pRSVIL2R-
 
b
 
1
 
A
 
 were constructed by cloning an Nhe1-Xba1 fragment
from pCMVIL2R-
 
a
 
5cyto or pCMVIL2R-
 
b
 
1A plasmids received from Su-
san LaFlamme (Albany Medical College, Albany, NY; Tahiliani et al.,
1997) into the Xba1 site of the pRSVneo vector. Clones were screened for
orientation by restriction digests. HA-tagged rat MEK1 and HA-tagged
rat constitutively active (CA) MEK S218/220D in pCMVneo vector i.e.,
sodium-deoxycholate, sodium-pyrophosphate, sodium-orthorandate (Catling
et al., 1995) were received from M. Weber (University of Virginia, Char-
lottesville, VA). The chicken paxillin cDNA, the Y118F, and the S188/
190A mutants in the pcDNA3.0neo vector (Brown et al., 1997) were re-
ceived from C. Turner. CD2FAK, CD2FAK(Y397F), and CD2FAK(K454R)
in CDM8 vector (Chan et al., 1994) were received from A. Aruffo.
 
Transfection and Flow Cytometry
 
Cells were transiently or stably transfected using a liposome-DNA solu-
tion as previously described previously (Sastry et al., 1996). In brief, repli-
cating myoblasts (passages 1–3) were plated on 60-mm tissue culture
plates coated with 0.1% gelatin in complete myoblast medium for 16–20 h.
Cells were incubated for 8–16 h in a solution of 8 
 
m
 
g of plasmid DNA and
50 
 
m
 
g of Lipofectamine (GIBCO BRL) in complete myoblast medium.
Transfected myoblasts were either washed with DMEM, refed with myo-
blast medium, and analyzed for transient expression or were trypsinized
and plated into selection medium on gelatin-coated tissue culture plates
(myoblast medium containing 0.4 mg/ml G418; GIBCO BRL) for 7–12 d
and then into myoblast medium containing 0.2 mg/ml G418 (maintenance
medium). For transfections with CD2FAK constructs, in order to gener-
ate stable populations, myoblasts were cotransfected with a pRSVneo or a
pEGFP-C1neo plasmid (Clontech, Palo Alto, CA) at 1:7 ratio (neo resis-
tance gene:CD2FAKcDNA) and selected in G418 as previously de-
scribed. The chicken 
 
a
 
6, human 
 
a
 
6A or 
 
a
 
6B, and 
 
a
 
61044t transfections
were selected and maintained on laminin-coated (20 
 
m
 
g/ml) tissue culture
plates. For coexpression of h
 
a
 
6A integrin and CD2-FAK cells were
cotransfected with pRc/CMVh
 
a
 
6A and CDM8CD2FAK vectors at a ratio
of 1:7, respectively. Transiently transfected cells were sorted by flow cy-
tometry (see below) for h
 
a
 
6A expression and the positive cells were
grown in G418 containing medium. CDM8CD2FAK vector does not carry
a neo resistance gene, therefore, only cells carrying both neo resistance
 
(h
 
a
 
6A positive) and able to replicate (CD2FAK positive) will survive.
Stable populations were analyzed both for h
 
a
 
6 and CD2 expression as de-
scribed below.
Both transiently and stably transfected (the 
 
a
 
5 phenotype was seen in
transient as well as stable transfectants) myoblasts were analyzed for sur-
face expression by flow cytometry as previously described (Sastry et al.,
1996). Chicken 
 
a
 
6A and 
 
a
 
61044t transfected cells were stained with a
chick 
 
a
 
6-specific polyclonal antibody, 
 
a
 
6ex, at 20 
 
m
 
g/ml in blocking buffer
(Hepes-Hanks PBS-CMF with 2% BSA) and FITC-labeled goat anti–rab-
bit IgG (Cappel). Human 
 
a
 
6A or B transfected myoblasts were analyzed
with the human 
 
a
 
6-specific mAb, 2B7, at 10 
 
m
 
g/ml in blocking buffer. Hu-
man 
 
a
 
5 transfected cells were stained with VIF4 mAb. Cells transfected
with CD2FAK or its mutants were stained with anti-CD2 mAb TS2/
18.1.1. Chicken 
 
b
 
1 transfected cells were stained with TS2/16 mAb against
the human 
 
b
 
1 epitope. IL2R-
 
a
 
5 or IL2R-
 
b
 
1A transfected cells were ana-
lyzed with an anti-IL2R antibody. The FACS profiles of the IL2R-
 
a
 
5 and
IL2R-cyto-transfected cells were not stable, and we were unable to obtain
populations greater than 40% positive, which were used for analysis. Flow
cytometry was performed on a EPICS cell sorter (Coulter Electronics,
Inc.) equipped with Cicero software for data analysis. As shown in Fig. 1,
expression levels were assayed by fluorescence activated cell sorting.
These profiles reflect enriched surface expression levels of ectopic inte-
grin subunits in transfected myoblasts used in experiments.
 
Cell Extracts, Western Blotting,
and Immunoprecipitation
 
For Western blotting and immunoprecipitation experiments, untrans-
fected and transfected myoblasts were plated on FN (UT and h
 
a
 
5 trans-
fected cells), on LM (UT and chicken 
 
a
 
6 and chicken 
 
a
 
61044t or human
 
a
 
6A transfected cells) or on gelatin (UT, PAX, and CD2FAK transfected
cells) for 24 h in complete myoblast medium. Since myoblasts will differ-
entiate in the absence of serum and also secrete their own matrix, we were
unable to test the effects of specific matrix ligands on the myoblast re-
sponse. Therefore, all assays were conducted in the presence of serum and
results are presented for steady state conditions. Cells were washed with
ice-cold PBS containing 1 mM Na-orthovanadate and lysed in ice-cold
modified RIPA extraction buffer (20 mM Tris-HCl, pH 7.4, 150 mM
NaCl, 0.5% NP-40, 1.0% Triton X-100, 0.25% sodium-deoxycholate, 2
mM EDTA, and 2 mM EGTA) with protease inhibitors (20 mg/ml leu-
peptin, 0.7 mg/ml pepstatin, 1 mM phenanthroline, 2 mM phenyl-methyl-
sulfonyl-chloride, and 0.05 units aprotinin) and phosphatase inhibitors (30
mM sodium-pyrophosphate, 40 mM NaF, 1 mM sodium-orthovanadate).
Protein content of the clarified lysates was determined using the Pierce
bicinchoninic acid (BCA) method with bovine serum albumin as the stan-
dard.
For phosphotyrosine Western blots, 10–15 
 
m
 
g of lysates were separated
on 10% SDS-PAGE gels (Laemmli, 1970) under reducing conditions and
transferred to nitrocellulose membranes (Towbin et al., 1979). Mem-
branes were blocked in 1% heat denatured BSA in TST buffer (10 mM
Tris-HCl, pH 7.5, 100 mM NaCl, 0.1% Tween-20) overnight at 4
 
8
 
C. Phos-
photyrosine containing proteins were detected by incubating the mem-
branes with the anti-phosphotyrosine mAb, PY20, and a secondary horse
radish peroxidase (HRP) conjugated anti–mouse antibody (Jackson Im-
munoResearch Labs) or with RC20H, a directly conjugated HRP anti-
phosphotyrosine Ab. Blots were visualized by chemiluminescence (Pierce
Chemical Co.). Membranes were exposed to X-ray film (Kodak, X-OMAT
AR) and developed in an automatic film processor. When indicated,
membranes were stripped in stripping buffer (62.5 mM Tris-HCl, pH 6.8,
2% SDS, and 100 mM 
 
b
 
-mercaptoethanol) for 30 min at 60
 
8
 
C and re-
probed with a different antibody.
For anti-MAPK Western blots, cells were trypsinized, washed once
with soybean trypsin inhibitor (0.5 mg/ml), washed twice in Puck’s Saline
G (GIBCO BRL) and resuspended in serum-free medium containing 2%
BSA. Cells were held in suspension for 1 h prior to plating on FN or LM in
complete myoblast medium for 24 h. Cell extracts were prepared in RIPA
buffer as described. 5 
 
m
 
g of cell lysates were separated on 12% SDS-
PAGE gels under reducing conditions and the proteins transferred to ni-
trocellulose membranes. The membranes were blocked in 3% nonfat dry
milk in TST overnight at 4
 
8
 
C. Active MAPK was detected by an anti-
active MAPK pAb (Promega). Membranes were stripped and reprobed
for total MAPK with an anti-erk1 mAb (Transduction Labs) or SC-94
anti-erk1 pAb (Santa Cruz Biotechnologies).
For paxillin, FAK, CD2-FAK, and HA immunoblot analysis, 5–20 
 
m
 
g
cell lysates were resolved on 7.5% SDS-PAGE gels under reducing condi- 
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tions and proteins transferred to nitrocellulose membranes. Membranes
were blocked in TST buffer containing 3% nonfat milk and the proteins
were detected with 165 mAb (anti-paxillin), BC3 pAb (anti-FAK), TS2/
18.1.1 mAb (anti-CD2), or 12CA5 mAb (anti-HA).
For FAK immunoprecipitations, 100 
 
m
 
g of RIPA lysate was mixed with
1 
 
m
 
l of anti-FAK mAb, 2A7, 50 
 
m
 
l of packed agarose anti–mouse beads
(blocked in 5% BSA; Sigma) in a final volume of 500 
 
m
 
l. The bead-anti-
body-antigen complex was incubated at 4
 
8
 
C for 2 h with continuous agita-
tion. For paxillin immunoprecipitations, 100 
 
m
 
g of cell lysate and 1 
 
m
 
l of
anti-paxillin mAb, 165 were incubated at 4
 
8
 
C with continuous agitation
for 1 h. In a separate tube, 50 
 
ml of packed protein A–agarose beads and
30 mg/ml rabbit anti–mouse IgG were incubated in lysis buffer for 1 h. The
antigen-antibody mixture was then added to rabbit anti–mouse–protein A
beads and incubated at 48C an additional 2 h. The beads were pelleted
gently and washed twice with lysis buffer. Bound protein was released
from the beads by boiling in 100 ml Laemmli sample buffer containing 5%
b-mercaptoethanol for 5 min. Equal aliquots of the precipitated protein
for each antibody were loaded onto 7% SDS-PAGE gels. The FAK IP
was blotted for FAK with C-20 and for phosphoFAK with RC20H. The
paxillin IP was blotted for paxillin with the 165 mAb or for phosphopaxil-
lin with RC20H. All immunoprecipitations and Western blots were de-
tected by chemiluminescence.
Immunofluorescence Staining
Cells were grown on FN- or LM-coated coverslips. Immunostaining was
done at room temperature. Cells were rinsed in PBS and fixed with 3%
formaldehyde in PBS for 15 min then permeabilized with 0.4% Triton
X-100 in PBS for 10 min, washed and blocked in 5% goat serum in PBS
(BB) for 30 min. Cells were incubated with primary Ab in BB for 30 min,
washed and incubated with FITC- or rhodamine-conjugated secondary
Ab (Cappel) and DAPI (Sigma Chemical Co.) for additional 30 min. Cov-
erslips were washed extensively and mounted in medium containing el-
vanol and p-phenylenediamine. Fluorescence was observed on a Zeiss
Axioplan microscope.
Alteration of MAPK activity and differentiation
MAP kinase activity was manipulated in ha6A transfected myoblasts by
coexpression of constitutively activate (CA) MEK1. Myoblasts were
cotransfected with pRc/CMVha6A and the HA-tagged pCMVneoMEK
S218/220D vectors at a ratio of 1:7, respectively. Cells were selected in
G418 and stable populations were sorted by flow cytometry for human
a6A expression as described. Cell lysates were analyzed for HA expres-
sion by Western blotting as described. Stably cotransfected cells were
plated on LM-coated plates and observed for 96 h.
To alter MAP kinase activity in ha5 transfected myoblasts, ha5-
expressing cells were grown in the presence of the specific MEK inhibitor
PD98059 (New England Biolabs) (Alessi et al., 1995). Transfected myo-
blasts were plated on FN-coated coverslips and on FN-coated TC plates.
After 8 h in complete myoblast medium, the first dose of the inhibitor was
added to the cells at 1, 10, 25, 50, or 100 mM final concentration. Cells
were grown for an additional 24 h and a second dose of the inhibitor was
added. After 24 and 48 h in presence of the inhibitor, coverslips were fixed
and immunostained for DAPI and muscle a-actinin. At the same time,
cells were extracted in RIPA buffer as described and lysates were ana-
lyzed by Western blotting for active MAPK and total erk1 expression as
described above.
Differentiation was scored using the fusion index, which is the percent-
age of total nuclei in myotubes as described in Sastry et al. (1996).
Results
Integrin a Subunit Cytoplasmic Domains Modulate 
Proliferative Signals through the b1 Subunit
We recently reported a specificity for integrin a subunits
and their cytoplasmic domains in controlling the prolifera-
tive to differentiative transition in primary quail myoblasts
(Sastry et al., 1996). Ectopic expression of the human a5
integrin subunit (ha5) enhanced the fraction of myoblasts
remaining in the proliferative phase and inhibited the in-
itiation of terminal differentiation. In contrast, ectopic
expression of the human a6A subunit of integrin (ha6A)
inhibited myoblast proliferation and promoted differentia-
tion. These effects resulted from a three- to fivefold in-
creased surface expression of the a5b1 or the a6Ab1 inte-
grin (and a two- to threefold increase in total b1 integrin,
see below) with little change in the relative expression of
other integrin a subunits. These findings suggested that
the a5 cytoplasmic domain promotes proliferative signals
whereas the a6A cytoplasmic domain inhibits prolifera-
tion and enhances the fraction of cells initiating terminal
differentiation.
To assess the contribution of these two cytoplasmic do-
mains, we first examined the effect of ectopic a5 and a6A
truncation mutants on myoblast proliferation and differ-
entiation. (Fig. 2 and Table I). As we reported previously,
Figure 1. Surface expression of ectopic integrins in primary quail
myoblasts. Myoblasts were transfected with (A) the human a5
(ha5) subunit, (B) the IL2Ra5 subunit, (C) a chimeric, chicken
b1A subunit, CH8, in which an extracellular region of the chick
sequence is replaced by the corresponding human b1 sequence to
create an epitope-tag, (D) the IL2R-b1A subunit, (E) the human
a6A (ha6A) subunit, (F) the IL2R-a6A subunit, or (G) the
a61044t deletion mutant and analyzed for cell surface expression
by flow cytometry. The ha5 (A) and ha6A (E) subunits were de-
tected with ha5 subunit-specific mAb, VIF4, or ha6A-specific
mAb, 2B7, respectively. (C) The CH8-b1A subunit was detected
with TS2/16, an anti–human b1 integrin mAb. An anti-IL2R
mAb was used to detect IL2R-a5 (B), IL2R-b1A (D), and IL2R-
a6A (F). These mAbs do not cross react with UT myoblasts. (G)
The a61044t deletion was detected with a polyclonal antibody,
a6ex, which recognizes both the endogenous quail a6 subunit as
well as the transfected chicken a6 subunit. qa6 is total a6 expres-
sion in untransfected cells and cha6 is total expression in trans-
fected cells. The shift in the expression profile reflects a two- to
threefold increase in total a6 integrin expression.Sastry et al. Integrins and Muscle Differentiation 1299
Figure 2. Effect of ectopic integrin subunits on muscle differenti-
ation. (A) Control untransfected (UT) myoblasts, a5 transfected
myoblasts,  a6A transfected myoblasts, or a61044t transfected
myoblasts were plated on coverslips in complete myo medium for
72 h and then double immunostained for a myogenic marker,
muscle a-actinin or DAPI to visualize nuclei. The UT and a6A
transfected cells show extensive fusion into multinucleated myo-
tubes, alignment of nuclei, and expression of muscle a-actinin.
Myoblasts expressing the a61044t subunit do not fuse into myo-
tubes and only a small percentage of cells express muscle a-acti-
nin. This phenotype resembles that of myoblasts expressing the
ectopic a5 subunit. (B) Fusion index, the percentage of total nu-
clei in myotubes. Ectopic expression of a61044t, b1A, or IL2R-
b1A inhibit myoblast fusion to a similar extent as the ectopic a5
subunit after 72 h of culture in serum-containing medium. Fusion
of IL2R-a5 or IL2R-a6A transfected cells resembles that of the
UT controls. Bar, 50 mm.The Journal of Cell Biology, Volume 144, 1999 1300
ectopic expression of the ha5 truncation, a5GFFKR,
which retains only the conserved GFFKR sequence, pro-
moted proliferation and inhibited differentiation similar to
the wild-type ha5 subunit (Sastry et al., 1996; Table I).
These findings suggest that the majority of the a5 cyto-
plasmic domain is not required for proliferative signals.
On the other hand, ectopic expression of an a6A trunca-
tion, a61044t, which deletes the COOH-terminal 11 amino
acid residues, restores proliferative signaling and produces
a phenotype similar to that of the ectopic a5 subunit. Myo-
blasts expressing a61044t remain in the proliferative phase
and do not differentiate even in high density cultures (Fig.
2). Like ha5 transfected myoblasts (Fig. 2 A), myoblasts
expressing a61044t do not express muscle a-actinin (Fig.
2), a myogenic differentiation marker, and exhibit a fusion
index of 5% (Fig. 2 B) after 72 h of culture in a rich me-
dium. This contrasts UT controls and ha6A transfected
cells (Fig. 2) where a significant fraction of cells express
muscle a-actinin and fuse into multinucleated myotubes
(Fig. 2 B). Preliminary mapping of the COOH-terminal 11
amino acids points to S1071 (in ha6A) as a key residue,
since its mutation to alanine produces a phenotype with
enhanced proliferation (data not shown). Furthermore,
the proliferation inhibiting effect of ha6 integrin is specific
for the a6A cytoplasmic domain isoform. Ectopic expres-
sion of the ha6B subunit in myoblasts promotes prolifera-
tion and inhibits differentiation (data not shown, Table 1).
Consistent with these results, the a6A isoform is the pre-
dominant a6 integrin expressed in striated muscle (Hoger-
vorst et al., 1993; and our own unpublished observations)
and in embryonic cells of determined lineage (Cooper et al.,
1991) whereas a6B is highly expressed in proliferating,
totipotent or undifferentiated ES cells. Taken together,
these observations suggest that the a5 and a6A cytoplas-
mic domains function differently: the a5 cytoplasmic do-
mains appears permissive whereas a discrete region of the
a6A cytoplasmic domain is inhibitory with respect to pro-
liferation.
To determine whether the a5 or a6A cytoplasmic do-
mains act directly or indirectly, we assayed the effects of
single-subunit cytoplasmic domain chimeras (LaFlamme
et al., 1992), IL2R-a5 or IL2R-a6A, on the ability of myo-
blasts to proliferate or differentiate. Ectopic expression of
either IL2R-a5 or IL2R-a6A had little detectable effect
on myoblast proliferation or differentiation (Fig. 2 B).
These cells behaved much like control, untransfected
(UT) myoblasts. Thus the a subunit cytoplasmic domains
do not directly initiate signals for myoblast proliferation or
differentiation.
How then do these two integrin a subunits regulate pro-
liferation and differentiation? Our observation that differ-
ent integrins, e.g., a5, a6B, and a61044t, all produce a sim-
ilar phenotype suggests an hypothesis in which these a
subunits influence the proliferative signaling through the
b1 subunit. In this view the a5 cytoplasmic domain (as well
as that of the a6B, a61044t, and perhaps others) would
permit signaling through the b1 subunit whereas the a6A
cytoplasmic domain would inhibit it. Previous studies have
shown that the a subunit cytoplasmic domain can regulate
b1 integrin localization to focal adhesions (Briesewitz et
al., 1993; Ylanne et al., 1993) and integrin activation
(O’Toole et al., 1991); both localization and activation,
however, are mediated by the b subunit cytoplasmic do-
main. Furthermore, the b1 cytoplasmic domain alone,
when expressed as a single subunit chimera, IL2R-b1, can
activate intracellular signals (Akiyama et al., 1994). To test
this hypothesis, we first determined whether overexpres-
sion of the chicken b1A subunit of integrin would increase
the fraction of proliferative myoblasts. We chose the b1A
isoform since it is predominant in replicating myoblasts
(Belkin et al., 1996). As reported in Sastry et al. (1996) ec-
topic expression of integrin a subunits also produces a
two- to threefold increase in total b1 expression with little
change in relative expression of the other endogenous a
subunit levels. The increase in total b1 expression main-
tains myoblasts in the proliferative phase and inhibits ter-
minal differentiation. Myoblasts with enhanced b1A ex-
pression grow to confluency but exhibit a fusion index of
only z10% compared with 60–70% for untransfected cells
(Fig. 2 E). Thus, increased b1A expression produces a
phenotype resembling that of increased ha5 subunit ex-
pression. This finding agrees with a similar result reported
previously for the b3 integrin (Blaschuk et al., 1997).
Next, we addressed whether the b1A cytoplasmic do-
main could independently affect myoblast proliferation or
differentiation through ectopic expression of the single
subunit chimera, IL2R-b1A. Previous studies show that
this chimera localizes in focal adhesions (LaFlamme et al.,
1992) and mediates enhanced integrin signaling (Akiyama
et al., 1994). Myoblasts expressing IL2R-b1A remain rep-
licative and proliferate until confluent with little detect-
able fusion into myotubes (Fig. 2 B). Like myoblasts
expressing ectopic a5 subunit, they also only exhibit sig-
nificant cell cycle withdrawal and differentiation if cul-
tured under serum-free conditions (Sastry et al., 1996 and
data not shown). These results demonstrate that the b1A
cytoplasmic domain is sufficient to transmit proliferative
signals and inhibit differentiation and thus modulate the
growth factor response. Further, ectopic expression of
IL2R-b1A can rescue the ha6A phenotype. Myoblasts
that coexpress IL2R-b1A and ha6A integrins proliferate
and differentiate like untransfected cells (data not shown;
Table I). Taken together, these findings suggest that pro-
liferative signaling through integrins occurs via the b1 sub-
unit and that different a subunit cytoplasmic domains can
modulate these signals. The effects of ectopic integrin sub-
units on myoblast proliferation and differentiation are
summarized in Table I.
Table I. Integrin Subunit Phenotypes
Transfected subunit Proliferation Differentiation
Control 11
a5 12
a6A 21
a5GFFKR 12
a6-1044t 12
a6B 12
b1 12
IL2a5 11
IL2b1 12
a6A 1 IL2b1 11Sastry et al. Integrins and Muscle Differentiation 1301
Ectopic Integrins Regulate FAK and Paxillin
We next sought to determine the effect of ectopic a5 or
a6A expression on b1A integrin signaling pathways. Since
integrins stimulate increased tyrosine phosphorylation of
several intracellular proteins (Burridge et al., 1992; Korn-
berg et al., 1992; Bockholdt and Burridge, 1993; Petch et al.,
1995; Vuori and Ruoslahti, 1995), we assayed the phos-
photyrosine profile of myoblasts expressing different
ectopic  a subunits. Immunoblotting with an anti-phospho-
tyrosine antibody shows that myoblasts ectopically ex-
pressing the ha5 integrin contain elevated tyrosine phos-
phorylation of proteins migrating in the molecular mass
ranges of 120–130 and 65–70 kD whereas cells transfected
with ha6A show a marked, general decrease in tyrosine
phosphorylation with no additional bands when compared
with UT controls (data not shown). These observations
are consistent with the phenotypic effects of the ectopic in-
tegrins presented above; i.e., the a subunits do not initiate
separate pathways. Thus, ectopic a5 expression permits
enhanced signaling through the b1A subunit, whereas the
a6A integrin suppresses these signals.
Next, we pursued the identities of the phosphoproteins
migrating at 120–130 and 65–70 kD. Focal adhesion kinase
(pp125FAK) and paxillin (pp68) are downstream targets
of integrin signaling pathways that migrate in these molec-
ular mass ranges (Burridge et al, 1992). Therefore, we as-
sayed the level of FAK and paxillin tyrosine phosphoryla-
tion in UT, ha5, and ha6A transfected myoblasts. A
Western blot of a FAK immunoprecipitation shows that
comparable levels of FAK were precipitated (Fig. 3 A,
lanes 1–3). The level of tyrosine phosphorylated FAK de-
creased in ha6A (Fig. 3 A, lane 6) versus ha5 transfected
(Fig. 3 A, lane 5) or UT myoblasts (Fig. 3 A, lane 4). How-
ever, the level of FAK tyrosine phosphorylation in ha5
and UT myoblasts does not differ (Fig. 3 A, lanes 4 and 5).
Immunodepletion of FAK from the lysate, followed by
Western blotting the supernatant for phosphotyrosine re-
veals an additional 120-kD band in the ha5 transfected
cells that could account for the observed increase in phos-
photyrosine (data not shown). Thus, whereas FAK phos-
phorylation decreases in myoblasts expressing ectopic a6A
integrin, it is unaffected by ectopic a5 expression.
To determine if paxillin phosphorylation is differentially
regulated in UT, ha5, and ha6A transfected myoblasts,
paxillin was immunoprecipitated with an anti-paxillin mAb.
In contrast to observations with FAK, we observed a ma-
jor difference in the level of paxillin expression between
UT and ha5 transfected myoblasts. As seen in Fig. 3 B,
paxillin is significantly upregulated in ha5 transfected myo-
blasts (Fig. 3 B, lane 2) when compared to UT (lane 1) or
ha6A transfected (lane 3) myoblasts. The comparable in-
tensity of a 55-kD band in the paxillin immunoprecipita-
tion corresponds to reduced IgG and serves as a loading
control. In addition to elevated levels of paxillin, a phos-
photyrosine Western blot of the paxillin immunoprecipita-
tion shows a concomitant increase in tyrosine phosphory-
lation of paxillin in ha5 transfected myoblasts (Fig. 3 B,
lane 5) compared to UT myoblasts (lane 4). Tyrosine
phosphorylation of paxillin in ha6A transfected cells (lane
6) is somewhat decreased relative to untransfected cells.
The enhanced paxillin expression observed in ha5 trans-
fected myoblasts does not arise as a direct effect of the ha5
integrin. Myoblasts expressing IL2R-b1A also show in-
creased paxillin expression whereas myoblasts expressing
IL2R-a5 do not (data not shown). Taken together, these
results indicate that enhanced paxillin expression accom-
Figure 3. Effect of ectopic a5 and a6A expression on tyrosine phosphorylation of FAK and paxillin. (A) FAK was immunoprecipitated
from UT, ha5, or ha6A transfected myoblasts with an anti-FAK antibody, mAb 2A7. Cell lysates were normalized for protein content.
Immunoprecipitated proteins were detected by Western blot for FAK with an anti-FAK polyclonal antibody, C-20 (left panel, lanes 1–3)
and for phosphoFAK with RC20H (right panel, lanes 4–6). The FAK Western blot shows that equivalent amounts of FAK were iso-
lated from the different cell types. An RC20H, phosphotyrosine, blot of the FAK immunoprecipitation (IP) shows that FAK phos-
phorylation decreases in ha6A transfected myoblasts (lane 6) compared with UT (lane 4) or ha5 (lane 5) transfected cells. (B) Paxillin
is upregulated in ha5 transfected myoblasts. Paxillin was immunoprecipitated with an anti-paxillin antibody, mAb 165, from equal pro-
tein quantities of UT, ha5, or ha6A transfected myoblast lysates. Immunoprecipitated proteins were resolved by SDS-PAGE, trans-
ferred to nitrocellulose and Western blotted for paxillin with mAb 165 (lanes 1–3) or phosphopaxillin with RC20H (lanes 4–6). Ha5
transfected myoblasts (lane 2) contain significantly elevated levels of paxillin compared to UT myoblasts (lane 1). UT (lane 1) and
ha6A transfected cells (lane 3) contain comparable amounts of paxillin. The paxillin band at 68 kD is indicated by an arrow. The 55-kD
IgG band is similar in all three lanes and serves as a loading control. On the right, phosphopaxillin increases in ha5 transfected myo-
blasts (lane 5) or slightly decreases in ha6A transfected cells (lane 6) compared to UT (lane 4).The Journal of Cell Biology, Volume 144, 1999 1302
panies increased a5 (or b1A) levels, whereas decreased
FAK phosphorylation coincides with increased a6A lev-
els. These data also suggest an uncoupling of FAK and
paxillin signaling.
Paxillin and FAK Regulate the Proliferative to 
Differentiative Transition
The altered expression and activation of paxillin and FAK
presented above prompted us to examine the effects of ec-
topic paxillin or FAK expression on myoblast prolifera-
tion and differentiation. As shown in Fig. 4 A (lane 2), the
level of paxillin expression increases when compared with
controls (Fig. 4 A, lane 1) after transfection of a paxillin
cDNA. Ectopic expression of wild-type paxillin inhibits
differentiation and results in a proliferative phenotype
(Fig. 5, Table II). Myoblasts expressing ectopic paxillin
proliferate until confluent but neither fuse into multinu-
cleated myotubes (Fig. 5) nor express muscle a-actinin
(Fig. 5). This phenotype is similar to that of ha5 trans-
fected myoblasts (Fig. 2). Thus ectopic paxillin expression
alone can recapitulate the effects of the ha5 or IL2R-b1A
integrin subunits. Paxillin expression levels in control cells
do not differ in replicating myoblasts versus differentiated
cultures (data not shown).
Two major sites of phosphorylation in paxillin in re-
sponse to adhesion to fibronectin are Y118 and S188/190
(Bellis et al., 1997). The tyrosine phosphorylation site,
Y118, is also the site phosphorylated by FAK (Bellis et al.,
1995). Therefore, we next tested the effect of a Y118F mu-
tation (Fig. 5) or the double mutation S188/190A on the
myoblast phenotype. When expressed in myoblasts (Fig. 4
A, lanes 3 and 4), neither of these mutants showed the en-
hanced proliferation seen when wild-type paxillin was ex-
pressed. Instead the paxillin mutants (Fig. 5) exhibited a
phenotype characteristic of UT myoblasts (Fig. 5, Table
II). This result suggests that these tyrosine and serine
phosphorylation sites in paxillin participate in prolifera-
tive signaling that regulates myoblast cell cycle with-
drawal.
Since FAK phosphorylation decreased in parallel with
the inhibition of proliferation in myoblasts expressing
ha6A integrin, we next tested the effect of an ectopic FAK
mutant, Y397F, which lacks the autophosphorylation site
and cannot bind src-family kinases (Schaller and Parsons,
1994), on proliferation and differentiation of myoblasts.
Since ectopic expression of soluble FAK often produces
short-lived or weak phenotypes (Richardson and Parsons,
1996), we used CD2-FAK, a membrane bound, chimeric
FAK construct, which is constitutively active (Chan et al.,
1994). Presumably, this results from increased adhesive
signaling that arises from its constitutive membrane asso-
ciation and consequent localization in focal adhesions.
Ectopic expression of CD2-FAKY397F, inhibits myoblast
proliferation while promoting differentiation (Fig. 5). These
cells are reminiscent of myoblasts transfected with the
ha6A integrin subunit except that their proliferation is not
inhibited as completely. They also show extensive fusion
into multinucleated myotubes (Fig. 5). Interestingly, myo-
blasts transfected with wild-type CD2-FAK (Fig. 4 B), re-
main proliferative and do not initiate terminal differentia-
tion (Fig. 5) when compared to UT controls. Fewer than
5% of CD2-FAK–expressing myoblasts fuse into multinu-
cleated myotubes (Fig. 5) or express muscle a-actinin (Fig.
5). Using FACS analysis of propidium iodide labeled cells
to measure G1/S progression, CD2-FAK transfected myo-
blasts show an increased ratio of G2 to G1 cells compared
to untransfected cells (data not shown). Similarly, ectopic
expression of CD2-FAK454, which is kinase defective,
also inhibits differentiation and promotes proliferation
(Fig. 5). Ectopic expression of wild-type CD2-FAK in
ha6A transfected myoblasts results in a proliferative phe-
notype. Myoblasts that coexpress CD2-FAK and ha6A in-
tegrin grow to confluency and do not differentiate (Fig. 5).
In sum, the ha6A phenotype can be recapitulated by ex-
pression of a FAK mutant expressed in control myoblasts
or rescued by coexpression of an activated form of FAK.
These data suggest that one potential mechanism by which
ha6A integrin inhibits myoblast proliferation is through
altering FAK phosphorylation. Thus, changes in the level
of focal adhesion signaling, through FAK or paxillin, sig-
nificantly affect the likelihood of myoblasts to proliferate
or withdraw from the cell cycle and differentiate. Table II
summarizes the effects of ectopic focal adhesion mole-
cules.
MAP Kinase Activity Modulates Integrin-mediated 
Proliferation and Differentiation
Several reports implicate MAP kinase in adhesion depen-
dent regulation of proliferation (Chen et al., 1994; Zhu
and Assoian, 1995; Wary et al., 1996; Miyamoto et al.,
Figure 4. Ectopic expression
of adhesive signaling mole-
cules. Myoblasts were trans-
fected with expression plas-
mids encoding a wild-type
chicken paxillin, paxillin mu-
tants Y118F and S188/190A,
or a membrane-targeted, chi-
meric FAK construct, CD2-
FAK. (A) Western blot anal-
ysis of myoblasts expressing
ectopic paxillin (lane 2) or
paxillin mutants Y118F (lane
3) or S188/190A (lane 4)
shows significant overexpres-
sion of these proteins compared with endogenous levels in un-
transfected myoblasts (lane 1). Paxillin was detected with mAb
165. (B) Expression of CD2-FAK on the cell surface was con-
firmed by flow cytometry using an anti-CD2 antibody.
Table II. Focal Adhesion Molecules and Differentiation
Transfected molecule Proliferation Differentiation
Untransfected 11
FAK 11
FAK(Y397F) 11
CD2-FAK 12
CD2-FAK(K454R) 12
CD2-FAK(Y397F) 11
PAX WT 12
PAX(S188/190A) 11
PAX(Y118F) 11Sastry et al. Integrins and Muscle Differentiation 1303
1996; Lin et al., 1997). In addition, MAP kinase activation
plays an important role in muscle differentiation (Bennet
and Tonks, 1997). Therefore, we investigated if the ectopic
integrins altered MAP kinase activation to control myo-
blast proliferation and differentiation. MAP kinase activa-
tion was assessed by immunoblotting cell lysates with an
antibody that specifically recognizes phosphorylated, or
active, forms of the 42- and 44-kD MAP kinases. Quail
myoblasts express the 44-kD MAP kinase, erk-1, which
was detected using an anti–erk-1 mAb (data not shown).
Fig. 6 shows Western blots of active MAP kinase in myo-
blasts expressing ectopic integrins. In all cases, control or
transfected cells were cultured for 24 h in complete serum-
containing medium before extraction. The results shown
Figure 5. Effect of ectopic adhesive signaling molecules on muscle differentia-
tion. (A) Myoblasts expressing CD2-FAK, wild-type paxillin, or paxillin
Y118F were grown in serum-containing medium for 72 h and then double im-
munostained for muscle a-actinin (mAA) and DAPI. Both the ectopic CD2-
FAK or wild-type paxillin inhibit expression of muscle a-actinin in the major-
ity of cells. In contrast, paxillin Y118F does not inhibit differentiation. These
cells fuse to form multinucleated myotubes and express muscle a-actinin.
Phase contrast pictures show that myoblasts expressing CD2-FAK-Y397 ex-
hibit extensive fusion into myotubes much like control, UT myoblasts,
whereas myoblasts that express CD2-FAK or that coexpress ha6A integrin
and CD2-FAK proliferate until confluent with minimal fusion. (B) Fusion in-
dex, the percentage of total nuclei in myotubes: CD2-FAK, CD2-FAK K454R,
or paxillin expression inhibits myoblast fusion when compared with UT con-
trols. The fusion of paxillin Y118F, paxillin S188/190A, or CD2-FAK-Y397F
transfected myoblasts is similar to UT controls. Bars: (fluorescence micro-
graphs) 50 mm; (phase micrographs) 35 mm.The Journal of Cell Biology, Volume 144, 1999 1304
reflect differences in steady state levels of MAP kinase ac-
tivity. Compared with UT myoblasts (Fig. 6, bottom, lane
1), ha5 (lane 2), or IL2R-b1A (lane 3) transfected myo-
blasts contain elevated levels of active MAP kinase. In
contrast, the level of active MAP kinase in ha6A trans-
fected cells is significantly decreased (Fig. 6, top, lane 3)
compared with controls (top, lane 1). The different inten-
sities for control levels of active MAP kinase (top versus
bottom) is due to different exposure times of the Western
blots to film. As presented earlier, the a6A cytoplasmic
domain truncation, a61044t, did not produce the prolifera-
tion inhibiting effects of ha6A integrin, and instead pro-
moted proliferation and inhibited cell cycle withdrawal.
This also altered the level of MAP kinase activation, as as-
sayed by Western blotting. Compared with myoblasts ex-
pressing ha6A, those expressing a61044t display enhanced
levels of active MAP kinase (Fig. 6, top, lane 2). Strip-
ping and reprobing these membranes for total erk1 levels
showed similar expression in all cells tested (data not
shown). Therefore, the level of MAP kinase activity de-
pends on the expression of specific integrins and their cy-
toplasmic domains.
We next investigated whether altering the activation
state of MAP kinase could reverse the ha5 or ha6A in-
duced phenotypes. We manipulated the level of active
MAP kinase through overexpression of MEK-1, an up-
stream activator of MAP kinase, or by addition of PD-
98059, a specific MEK inhibitor (Alessi et al., 1995).
Cotransfection of myoblasts with constitutively active
MEK (CA-MEK; Catling et al., 1995) and ha6A integrin
restores a proliferative phenotype to myoblasts expressing
ha6A. These cells stably express both the ha6A subunit
(Fig. 7 B) and CA-MEK (Fig. 7 A) after drug selection
and continue to proliferate for the lifetime of the cells in
culture. FACS analysis of propidium iodide labeled cells
shows an increased ratio of G2 to G1 cells in the ha6A/
CA-MEK cotransfectants (data not shown). As reported
previously (Sastry et al., 1996), we were unable to isolate
cells stably overexpressing only the a6A integrin. The
ha6A-CA-MEK transfected cells are similar to the ha5
transfected myoblasts; i.e., they remain proliferative and
do not differentiate appreciably (Fig. 7 E) compared with
ha6A transfected (Fig. 7 D) or UT cells (Fig. 7 C). The
level of active MAP kinase is enhanced in ha6A-CA-
MEK cells (Fig. 6, top, lane 4) when compared to ha6A
(Fig. 6, top, lane 3) or UT (Fig. 6, top, lane 1) myoblasts.
Interestingly, we were unable to obtain stable expression
of CA-MEK in untransfected, control myoblasts. Presum-
ably, excessive levels of activated MEK, or MAP kinase,
leads to increased cell death or decreased cell growth.
We next determined whether decreasing the level of ac-
tive MAP kinase, using the specific MEK inhibitor PD-
98059, would reverse the ha5 phenotype. ha5 transfected
myoblasts were plated onto FN-coated plates in serum-
containing medium and allowed to attach for 8–12 h. In-
creasing concentrations of the MEK inhibitor, PD-98059
were then added for an additional 24–48 h. With increas-
ing inhibitor concentration, the fraction of differentiated
cells increased, whereas at high inhibitor concentrations,
the total number of cells decreased, presumably due to in-
hibited proliferation (Fig. 8 and data not shown). After 48 h,
ha5 transfected myoblasts treated with a 25 mM or greater
concentrations (Fig. 8 C) of the MEK inhibitor displayed
marked differentiation into myotubes compared with un-
treated ha5 transfected cells (Fig. 8 B) resembling UT
controls (Fig. 8 A). A Western blot for the level of active
MAP kinase shows that increasing concentrations of PD-
98059 reduces MAP kinase activity in ha5 transfected cells
(Fig. 8 E). Taken together, our observations demonstrate
that quantitative changes in integrins closely parallels
changes in MAP kinase activation. Moreover, the level of
active MAP kinase appears to be a critical determinant of
myoblast proliferation versus differentiation.
Discussion
In this study we addressed the mechanisms by which inte-
grin a subunits modulate intracellular signal transduction
events that lead to phenotypic changes in cell proliferation
and differentiation. Skeletal myoblasts are well suited for
this kind of study. The probability that a myoblast with-
draws from the cell cycle and initiates terminal differentia-
tion is highly sensitive to environmental cues including
growth factors and ECM components (Sastry et al., 1996).
The sharply contrasting effects of ectopic a5 or a6A inte-
grin on myoblast proliferation and differentiation there-
fore provide a useful system to address a subunit specific
signaling and the mechanisms by which integrins regulate
the myoblast decision to withdraw from the cell cycle and
initiate terminal differentiation. The data presented here
demonstrate that the ectopic a subunits differentially reg-
ulate proliferative signaling through the b1 subunit. They
also demonstrate that paxillin, FAK, and MAP kinase
serve as important regulators of cell cycle withdrawal and
the onset of terminal differentiation. Finally, our results
show that the decision to withdraw from the cell cycle and
initiate terminal differentiation is highly poised and reg-
Figure 6. Ectopic integrins
regulate MAP kinase activ-
ity. Different ectopic inte-
grins alter activation of the
level of erk-1 MAP kinase in
24-h cultures grown in serum-
containing medium. MAP ki-
nase activity was determined
by Western blotting with an
antibody that recognizes du-
ally phosphorylated, active
MAP kinase. Top panel: ec-
topic ha6A expression (lane
3) suppresses MAP kinase
activation compared to un-
transfected controls (lane 1).
Ectopic expression of the
a6A truncation mutant,
a61044t (lane 2), does not in-
hibit MAP kinase activation.
Coexpression of ha6A and
constitutive MEK-1 reverses the ha6A inhibition of MAP kinase
activity (lane 4). (Bottom) Ectopic ha5 (lane 3) or IL2R-b1A
(lane 2) expression enhance MAP kinase activation compared to
untransfected controls (lane 1). The differing intensities for un-
transfected controls between the top and lower panels reflect dif-
ferent exposure times of the membranes to film.Sastry et al. Integrins and Muscle Differentiation 1305
ulated by quantitative changes in the level of MAP ki-
nase activation, which in turn is regulated by quantitative
changes in levels of integrin signaling. These observations
provide a rationale for: (a) the apparently disparate re-
quirements of different muscle cell lines and primary cul-
tures for proliferation and cell cycle withdrawal, (b) the
modulation of integrin subunits during muscle differentia-
tion (Menko and Boettiger, 1987; Muschler and Horwitz,
1991; Bronner-Fraser et al., 1992; Lakonishok et al., 1992;
Blaschuk and Holland, 1994; Boettiger et al., 1995) and (c)
the hyperproliferative phenotypes observed when inte-
grins are modulated in some other cell types (Carroll et al.,
1995).
How does the a5b1 integrin potentiate signaling while
the a6b1 integrin attenuates it? Our data show that the
b1A subunit (i.e., cytoplasmic domain) is sufficient to
transmit proliferative signals. The a5 subunit is permissive
and allows b1 signaling while the a6A inhibits it. Previous
studies indicate that signaling through integrins requires
receptor ligation or clustering into focal adhesions (Korn-
berg et al., 1991; Miyamoto et al., 1996). In the myoblast
system, both the ectopic a5 and a6A subunits form func-
tional receptors with the endogenous b1 subunit for FN or
LM, respectively (data not shown, and Sastry et al., 1996).
Therefore, the differences in signaling we observe are
most likely not due to an inability to bind ligand. Further-
more, since IL2R-b1A alone stimulates proliferation, re-
ceptor-ligation does not appear necessary except perhaps
to form focal adhesions. Our observation used cells cul-
tured on a complex ECM containing serum and secreted
FN, also indicating that receptor ligation may not be a crit-
ical factor, for the inhibitory effects of ectopic a6. Interest-
ingly, the a5b1 and the a6b1 integrins exhibit distinct sub-
cellular distributions in muscle when cultured on the
appropriate matrix ligand (Sastry, S., J. Muschler, and M.
Lakonishok, unpublished observations). The a5b1 inte-
grin localizes in focal adhesions on a FN substrate. In con-
trast, the a6b1 integrin displays a diffuse cell surface distri-
bution on a laminin substrate. Since the initiating event for
signaling through integrins is receptor clustering, the con-
trasting localizations of a5b1 and a6b1 could reflect a dif-
ference in their ability to signal. The clustering of integrins
recruits signaling proteins into the focal adhesion signaling
complex (Miyamoto et al., 1995). In this view, the a5b1 in-
tegrin (or any other b1 integrin with a permissive a sub-
unit) recruits and activates proteins like FAK, paxillin,
and MAP kinase to stimulate signaling. The a6b1 integrin,
though able to bind to LM, is unable to recruit and/or acti-
vate the requisite signaling complex.
In the context of a model in which integrin signaling oc-
curs primarily through the b1 subunit, how might the a
subunits regulate signaling? A possible mechanism is that
the a5 and a6A cytoplasmic domains differentially regu-
late the accessibility of binding sites on the b1 cytoplasmic
domain. The a5 subunit (and likely several other a subunits)
would permit exposure of critical binding sites, whereas
the a6A subunit would mask them. A similar mode of reg-
ulation is proposed for the a subunit cytoplasmic domain
Figure 7. The effect of ectopic a6A integrin on proliferation is reversed by MAP kinase activa-
tion. (A) Constitutive HA-tagged MEK-1 (CA-MEK1) is efficiently expressed in control (lane 3)
and ha6A transfected (lane 2) myoblasts in a transient transfection. MEK-1 expression is detected
by a Western blot with an antibody specific for the HA epitope. (B) FACS analysis of ha6A inte-
grin expression in myoblasts cotransfected with CA-MEK1. The ha6A subunit was detected with
mAb 2B7, which is specific for ha6A. Both the ha6A integrin and CA-MEK are stably expressed
in the double transfected cells after G418 selection. After 72 h of culture in serum-containing me-
dium, ha6A/CA-MEK1 transfected myoblasts (E) grow to confluency with little detectable fusion
into myotubes while both UT (C) and ha6A transfected (D) myoblasts differentiate and form myo-
tubes. Bar, 40 mm.The Journal of Cell Biology, Volume 144, 1999 1306
in the ligand-dependent localization of integrins in focal
adhesions (Briesewitz et al., 1993; Ylanne et al., 1993).
Other models of regulation are also possible. They include
a steric masking of the b1 cytoplasmic domain by the a6
cytoplasmic domain through interaction with an inhibi-
tory binding protein, or through an a6-mediated signaling
event that results in the activation of a phosphatase. The
observation that IL2R-b1A expression rescues the ha6A
phenotype, suggests that a6A masks some critical site on
b1A cytoplasmic domain. Our observation that ectopic
IL2R-a6A does not inhibit proliferation argues against an
a6b1 binding protein but does not rule it out.
The critical regulatory site(s) within the a6 cytoplasmic
domain appears to reside in the eleven COOH-terminal
amino acids of the a6A sequence (Table I). This COOH-
terminal region of the a6A cytoplasmic domain contains
two putative serine phosphorylation sites (Shaw et al.,
1990; Delwel et al., 1993), which could potentially partici-
pate in negative regulation of signaling by the a6A inte-
grin. Preliminary mapping of the a6A cytoplasmic domain
implicates one of these phosphorylation sites in a6A
(S1071) in inhibition of proliferation (unpublished obser-
vations). However, the physiological relevance of a6 phos-
phorylation in this system is not yet clear.
Our observations also identify important roles for intra-
cellular components of integrin signaling pathways in reg-
ulating cell cycle withdrawal and the onset of terminal dif-
ferentiation. FAK and paxillin, stand out as potential
integrin proximal mediators of adhesive signaling. These
proteins are phosphorylated on tyrosine in response to cell
adhesion to ECM in many cell types (Guan et al., 1991;
Burridge et al., 1992; Hanks 1992; Kornberg et al., 1992;
Schaller et al., 1992; Schwartz et al., 1995). In addition,
both FAK and paxillin bind to synthetic peptides derived
from the b1A cytoplasmic domain (Schaller et al., 1995).
However, their role in cell cycle withdrawal and the onset
of terminal differentiation is not well understood. Some
evidence implicates FAK in proliferation and cell survival.
Displacement of endogenous FAK from focal adhesions in
endothelial cells, through microinjection of the focal adhe-
sion targeting domain, interferes with cell cycle progres-
sion (Gilmore and Romer, 1996) resulting in apoptosis.
Similarly, microinjection of b1A peptides corresponding
to the FAK binding site, or anti-FAK antibodies induces
apoptosis in cultured fibroblasts (Hungerford et al., 1996).
Expression of constitutively active FAK, CD2-FAK, in ep-
ithelial cells protects them from apoptosis (Frisch et al.,
1996).
Our data support a requirement for FAK activation in
basal myoblast proliferation; but it does not contribute to
the enhanced proliferation, i.e., the inhibited cell cycle
withdrawal, observed in cells expressing ectopic a5. Phos-
phorylation of FAK on tyrosine is not significantly altered
in myoblasts expressing ectopic a5 integrin. In most cell
types, FAK phosphorylation peaks within 1 h after cell at-
tachment to the ECM (Guan et al., 1991; Burridge et al.,
1992; Hanks et al., 1992; Schaller et al., 1992). A transient
increase in FAK phosphorylation is observed in a5 trans-
fected myoblasts after initial attachment on a FN substrate
(data not shown). However, we do not observe a sustained
increase in FAK activation that coincides with the sus-
tained proliferative phenotype induced by ectopic a5 inte-
grin. Additionally, overexpression of FAK, as well as sev-
eral FAK mutants and FRNK (Richardson and Parsons,
1996), had no detectable effect on myoblast proliferation
or differentiation (unpublished observations). However,
ectopic expression of CD2-FAK, a membrane-bound, acti-
vated form of FAK, does promote proliferation and in-
hibit differentiation, thus resembling the effect of ectopic
a5 or b1A integrin. Presumably this arises because CD2-
FAK is targeted to the membrane and therefore available
to recruit additional adhesive signaling complexes. In con-
trast, the level of FAK phosphorylation is reduced in myo-
blasts expressing ectopic a6A integrin, correlating with
the increased cell cycle withdrawal. Ectopic expression
of CD2-FAKY397F, which lacks an autophosphorylation
Figure 8. The effect of ectopic a5 integrin on proliferation and
differentiation requires active MAP kinase. MEK-1 inhibitor,
PD98059, was added to ha5 transfected myoblasts. After 72 h in
serum-containing medium, ha5 transfected cells treated with
PD98059 exhibit extensive fusion into myotubes (C) and resem-
ble control, UT myoblasts (A). (B) Untreated ha5 transfected
myoblasts grow to confluency without significant fusion. (E) In-
creasing concentrations of PD98059 reduce the level of active
MAP kinase. At greater than 25–50 mM inhibitor, the level of active MAP kinase in ha5 transfected cells is reduced to that observed in
UT controls (D). Bar, 30 mm.Sastry et al. Integrins and Muscle Differentiation 1307
site, acts as a dominant negative and inhibits proliferation
and promotes differentiation, thus revealing its role in
basal proliferation. This phenotype is similar to but less
dramatic than that of ectopic a6A integrin expression. It is
interesting to note that Y397 is a binding site for src family
kinases (Schaller and Parsons, 1994). Finally, coexpression
of CD2-FAK and ha6A results in proliferation. Taken to-
gether, these observations are consistent with a role for
FAK phosphorylation in the basal level of proliferation
seen in control myoblasts and show that it lies on the path-
way downstream of the a6A-mediated inhibition of the b1
integrin signaling.
In contrast to FAK, both the expression and subsequent
tyrosine phosphorylation of paxillin are significantly en-
hanced in a5 transfected myoblasts when compared to un-
transfected or a6A transfected cells. A role for paxillin in
proliferation or differentiation has not been demonstrated
previously. Paxillin is a multidomain adapter protein that
mediates numerous interactions with different signaling
proteins, including FAK (Schaller and Parsons, 1994).
However, paxillin has no known enzymatic activity. Pax-
illin does contain multiple LIM domains, which are
involved in protein-protein interactions and targeting
of paxillin to focal adhesions (Turner and Miller, 1994;
Brown et al., 1996). Finally, paxillin has been implicated in
growth factor dependent differentiation where an increase
in its tyrosine phosphorylation correlates with neuronal
differentiation (Khan et al., 1995; Leventhal and Feldman,
1996). In myoblasts, the upregulation of paxillin in re-
sponse to ectopic a5 integrin coincides with a proliferative
phenotype, which can be recapitulated by ectopic expres-
sion of paxillin. Our results with paxillin mutants implicate
both the Y118F and S188/190A phosphorylation sites as
key. Whereas the mechanism by which paxillin inhibits
cell cycle withdrawal, i.e., stimulates proliferation, is not
known, increased paxillin expression and phosphorylation
enhances the formation of adhesive signaling complexes as
do CD2-FAK and ectopic a5 expression (unpublished ob-
servation). In contrast to the significant effects of ectopic
a5 expression on paxillin expression and phosphorylation,
ectopic a6A expression had only a very modest effect on
paxillin phosphorylation and none on expression. Coex-
pression of paxillin and ha6A did not relieve the a6A phe-
notype (data not shown). Thus the level of paxillin ex-
pression and phosphorylation appear to contribute the
myoblast decision to proliferate or differentiate. However,
it may not play a role in the inhibition of proliferation by
ectopic a6A expression. It is noteworthy that our results
also indicate an uncoupling of FAK and paxillin signaling,
since they are not activated in parallel as reported for fi-
broblasts (Burridge et al., 1992).
Although our results demonstrate an inhibitory role for
the a6A integrin in signaling, this integrin is capable of ac-
tivating intracellular signals in other cell systems. In mac-
rophages, for example, a6Ab1-mediated attachment to
laminin leads to increased tyrosine phosphorylation of
paxillin (Shaw et al., 1995). In addition, antibody cluster-
ing of the a6 integrin in endothelial cells leads to a distinct
profile of tyrosine phosphorylated proteins, which do not
include FAK or paxillin (Jewell et al., 1995).
The contrasting effects of ectopic a5 or a6A integrin ex-
pression on MAP kinase activation suggests quantitative
changes in MAP kinase activation plays a major role in
regulating myoblast cell cycle withdrawal. Perturbing the
ratio of different integrins in the cell alters the level of
MAP kinase activation. In contrast to our findings, the
a6A integrin, but not the a6B subunit, activates MAP ki-
nase in macrophages (Wei et al., 1998). Cell type differ-
ences likely explain these conflicting observations. In the
muscle system, the effect of ectopic a5 or a6A integrins
and their mutants on MAP kinase activation parallels their
phenotypic effects on myoblast proliferation and differen-
tiation. Likewise, perturbing the activation state of MAP
kinase, using a MEK inhibitor or CA-MEK, can overcome
the integrin induced effect on both MAP kinase activity
and the myoblast phenotype. Consistent with these results,
the activation of MAP kinase is apparently an important
determinant of myogenic differentiation. Inactivation of
MAP kinase by overexpression of MAP kinase phos-
phatase renders C2C12 myoblasts insensitive to mitogenic
stimuli, favoring expression of muscle-specific genes like
myoD (Bennet and Tonks, 1997). Finally, our data show
that MAP kinase activation in myoblasts requires both ad-
hesive and growth factor signals. We do not observe active
MAP kinase in the absence of serum or on a non-specific
adhesive substrate like poly-L-lysine (unpublished obser-
vations). Taken together, these findings reveal a role for
integrins in controlling myoblast proliferation and differ-
entiation through a pathway that regulates the level of
MAP kinase activation.
The ability of different integrins to activate MAP kinase
is proposed to occur via an association of integrins with
the adaptor protein, shc. In fibroblasts or endothelial cells,
a5b1 and several other integrins interact with shc and thus
can activate MAP kinase whereas the a6 integrin cannot
bind shc or activate MAP kinase (Wary et al., 1996). How-
ever, the interaction with shc does not require integrin cy-
toplasmic domains. Our data do not preclude an involve-
ment of shc; the increase in MAP kinase activation seen in
response to the a61044t truncation may reflect a differ-
ence in the binding of shc, or an unidentified adapter or
regulatory protein.
Our observations can be summarized in a working
model for adhesive regulation of myoblast withdrawal
from the cell cycle and the onset of terminal differentia-
tion. In this model, the myoblast decision to proliferate or
withdraw from the cell cycle is regulated, at least in part,
by the level of activated MAP kinase. This decision ap-
pears highly poised and sensitive to quantitative fluctua-
tions in the level MAP kinase activation: increased MAP
kinase activation favoring proliferation and decreased
MAP kinase activation favoring cell cycle withdrawal.
MAP kinase activation, in turn, is regulated by the signal-
ing emanating from both adhesive and growth factor path-
ways. Evidently, neither pathway alone is sufficient to sus-
tain proliferation. The absence of either growth factor or
adhesive signaling promotes cell cycle withdrawal and the
onset of terminal differentiation, which appears to func-
tion as a default. At one level, the synergy is compatible
with an additive model since increased signaling via either
enhanced growth factor or adhesive signaling leads to a
decreased probability of cell cycle withdrawal. However,
the synergy between the growth factor and adhesive sig-
naling systems likely has interactions that are more consis-The Journal of Cell Biology, Volume 144, 1999 1308
tent with an additive, threshold model, in which signals are
required from both the growth factor and adhesive path-
ways. MAP kinase is not activated and targetted to the nu-
cleus in cells that are either adhering to a nonspecific ad-
hesive substrate like poly-L-lysine or that lack serum
growth factors. Recent studies point to RAF as an integra-
tion point for adhesive and growth factor signals (Chen et
al., 1996; Renshaw et al., 1997; Howe et al., 1998).
This working model provides a rationale for diverse ob-
servations on the myoblast decision to proliferate or dif-
ferentiate. Infection of myoblasts with viruses encoding src
family kinases (Alemo and Tato, 1987) or erbB (Olson,
1992), a truncated form of the EGF receptor with intrinsic
tyrosine kinase activity, or the ectopic expression of CD2-
FAK or paxillin all inhibit cell cycle withdrawal and pro-
duce a proliferative phenotype similar to that of myoblasts
ectopically expressing the a5 integrin. It is likely that this
arises from increased adhesive and/or growth factor sig-
naling resulting in increased MAP kinase activation. Simi-
larly, the general requirement for high confluency and low
serum for differentiation of diverse muscle cell lines likely
also appears to reflect enhanced mitogenic signaling, i.e.,
increased MAP kinase activation, which in this case results
from immortalization or adaptation to culture. Previous
reports show alterations in the expression of integrin sub-
units during muscle differentiation, our results raises the
possibility that they contribute to cell cycle withdrawal
and the onset of terminal differentiation. Finally, our stud-
ies appear pertinent to keratinocyte proliferation in vivo
as well as to myoblast differentiation in vitro. Transgenic
mice expressing two- to threefold increased expression of
a5b1 or a2b1 integrins exhibit epidermal hyper-prolifera-
tion, perturbed keratinocyte differentiation and other fea-
tures of psoriasis, a skin disease (Carroll et al., 1995). This
epidermal hyper-proliferation is similar to our observa-
tions on myoblasts expressing ectopic a5 integrin. Our
working model provides a possible mechanism. Therefore,
it is likely that quantitative changes in mitogenic signaling
through alterations in adhesive signaling produces pheno-
typic alterations that operate through common mecha-
nisms in diverse systems.
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